Flecainide is a class Ic anti arrhythmic agent. Flecainide is useful in treating patient with severe ventricular arrhythmias who is unresponsive to other forms of treatment. Flecainide is also used as preventive measure against paroxysmal atrial fibrillation.
Flecainide will acts by blocking the opening of the sodium ion channels which will reduce the rates of depolarisation of the phase 0. This will lead to an increase in the refractory period with slowness in the atrioventricular conduction ( AV conduction). Flecainide will react at a slower rates to sodium channel than other class of anti arrhythmic agents.
Flecainide is a well known anti dysrhythmic agent which is excreted unchanged in the urine. Flecainide is administered orally with half life of 20 hours.
The common side effects of flecainide may include ventricular fibrillation which occur post infarction/ increase the risk of fatality and negative inotropic effects as well as ventricular dysrhythmic effects.